CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

Group 1 - CervoMed Inc. will host a conference call and webcast on July 28, 2025, to share primary endpoint results from the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies [1][2] - The RewinD-LB study is a randomized, 16-week, double-blind, placebo-controlled trial involving 159 patients, with a subsequent 32-week extension phase [4] - The study is primarily funded by a $21.3 million grant from the National Institutes of Health's National Institute on Aging [4] Group 2 - Neflamapimod is an investigational oral small molecule that inhibits p38 mitogen-activated protein kinase alpha, aimed at treating synaptic dysfunction in age-related neurologic disorders [5] - The primary outcome measure of the RewinD-LB study is the change in the Clinical Dementia Rating – Sum of Boxes, with secondary endpoints including various cognitive assessments [4] - The study excludes patients with Alzheimer's disease co-pathology, focusing on those with "pure" dementia with Lewy bodies [4]